The Use of Central Laboratories and Remote Electronic Data Capture to Risk-Adjust Therapy for Pediatric Acute Lymphoblastic Leukemia and Neuroblastoma
- 28 February 2010
- journal article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 37 (1), 53-59
- https://doi.org/10.1053/j.seminoncol.2009.12.007
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastomaJournal of Clinical Oncology, 2007
- Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) studyJournal of Clinical Oncology, 2007
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Blood, 2006